Stocks related to the pharma industry were trading higher on the BSE, as Crisil in its latest report has said the Indian pharmaceuticals industry is expected to log in a revenue growth of 8-10 per cent in current fiscal (FY24) aided by a steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds. It stated a study of 186 drug makers, which accounted for about half of the Rs 3.7 lakh crore annual revenue of the sector last fiscal, indicates as much.
Sun Pharmaceutical Industries is currently trading at Rs. 1151.25, up by 14.15 points or 1.24% from its previous closing of Rs. 1137.10 on the BSE.
Natco Pharma is currently trading at Rs. 822.65, up by 10.30 points or 1.27% from its previous closing of Rs. 812.35 on the BSE.
Aurobindo Pharma is currently trading at Rs. 868.05, up by 0.35 points or 0.04% from its previous closing of Rs. 867.70 on the BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: